Cetuximab/encorafenibDevelopment of drug resistance and off-label use: case report

被引：0

|

作者：

机构：

来源：

Reactions Weekly | 2022年 / 1894卷 / 1期

关键词：

D O I：

10.1007/s40278-022-10216-8

中图分类号：

学科分类号：

摘要：

引用

收藏

页码：103 / 103

相关论文

共 50 条

[31] RituximabCellulitis and off-label use: case report
Reactions Weekly, 2022, 1911 (1) : 363 - 363
[32] IbrutinibNeutropenia and off-label use: case report
Reactions Weekly, 2020, 1787 (1) : 271 - 271
[33] AntineoplasticsPancytopenia and off-label use: case report
Reactions Weekly, 2020, 1825 (1) : 39 - 39
[34] DexmedetomidineHypotension and off-label use: case report
Reactions Weekly, 2019, 1749 (1) : 172 - 172
[35] AzithromycinCardiotoxicity and Off-label use: case report
Reactions Weekly, 2023, 1953 (1) : 100 - 100
[36] LinezolidLeukopenia and off-label use: case report
Reactions Weekly, 2025, 2044 (1) : 180 - 180
[37] MirtazapineOtotoxicity and off-label use: case report
Reactions Weekly, 2024, 2037 (1) : 255 - 255
[38] ClozapineSyncope and off-label use: case report
Reactions Weekly, 2022, 1930 (1) : 198 - 198
[39] AfatinibVarious toxicities and drug resistance following off-label treatment: case report
Reactions Weekly, 2021, 1880 (1) : 22 - 22
[40] AntineoplasticsReactive cutaneous capillary endothelial proliferation, emergence of drug resistance and off-label use: case report
Reactions Weekly, 2022, 1921 (1) : 41 - 41

← 1 2 3 4 5 →